Psilocybin in the Treatment of Smoking Addiction - Albert Garcia-Romeu
https://2013.psychedelicscience.org https://www.maps.org Psilocybin in the Treatment of Smoking Addiction: Psychological Mechanisms and Participant Account Albert Garcia-Romeu, Ph.D. Anthropological evidence and early experimental studies suggest that structured administration of 5-HT2A agonist hallucinogens (e.g., LSD and psilocybin) may have potential in treating addictions, including alcoholism and opioid dependence. In order to assess the feasibility of psilocybin as an adjunct to addiction treatment, we have developed a smoking cessation protocol integrating elements from Cognitive-Behavioral Therapy and mindfulness with three sessions in which moderate to high doses of psilocybin (20, 30, and 30 mg/70 kg) are administered. Pilot results have been positive, with biologically verified abstinence (CO and cotinine) achieved by 100% of participants in the current sample of nine volunteers, ranging from five weeks to 12 months abstinence depending on their current phase of treatment. Quantitative results generally showed increases in smoking abstinence self-efficacy, confidence, purpose in life, and improved concentration, as well as decreases in withdrawal related anxiety, craving, temptation, desire, and intention to smoke. Participants attributed an important role to mystical-type effects occasioned by psilocybin. These findings are limited by the small participant sample; however this pilot study is ongoing and additional volunteers are currently enrolled. Implications and future directions for research will be discussed. Albert Garcia-Romeu is a postdoctoral fellow at Johns Hopkins University School of Medicine, where he is currently researching the effects of psychedelic compounds in human subjects, with a focus on psilocybin as a potential aid in the treatment of addiction. He received his doctorate at the Institute of Transpersonal Psychology where he studied the measurement and experience of self-transcendence in healthy adults. Other research interests include the neural and genetic correlates of self-transcendence, potential clinical applications of mindfulness and altered states of consciousness, psychospiritual development, integral theory, and the synthesis of diverse scientific and spiritual paradigms towards novel understandings of consciousness.

The Beckley-Imperial Psychedelic Research Program - David Nutt

How to Quit Smoking: My Experience Quitting Cigarettes After 10 Years

How to Quit Smoking, Vaping or Dipping Tobacco

Clinical Perspectives in Managing High Dose Psilocybin Sessions - Brian Richards & Mary Cosimano

Speak Your Mind - How to Quit Smoking When You Believe You Can't

The Use of LSD, Psilocybin, and Bromo-LSD for the Treatment of Cluster Headaches - Torsten Passie

Psilocybin, Addiction, and End of Life - Stephen Ross

IAS Distinguished Speaker Series - Albert Garcia-Romeu, PhD - August 20, 2025

Panel – Prof. Dr. Albert Garcia-Romeu, Dr. Samuli Kangaslampi - 'Minds or Social Systems'

What is the Single Best Thing You Can Do to Quit Smoking?

"How to Change Your Mind": Michael Pollan in conversation with Dacher Keltner

The Life of a Functional Cocaine Addict-Eric B. Zink

30. Schizophrenia by Robert Sapolsky

Everything you need to know about psilocybin therapy

Psychedelic Treatment of Tobacco Use Disorder with Matthew W. Johnson, PhD

What Can Buddhist Meditation Teach Us About Psychedelic Science? - Katherine MacLean

The Essence of Psychedelic Therapy - Peter Oehen

TEDxMidAtlantic - Roland Griffiths - 11/5/09

Beyond Fear: MDMA and Emotion - Matthew Baggott

